With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Dennison also describes how CRISPR screening tools will be key to further ... I think the reason is that the clinical team is relatively small, so they can buy into the project. We've got good links ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Many healthcare stocks are good alternatives for investors to buy now. Some top candidates ... The Motley Fool has positions in and recommends CRISPR Therapeutics, Intuitive Surgical, TransMedics ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

and leveraging […] We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...